KX2-361: Phase I started

Kinex began an open-label, dose-escalation, U.S. Phase I trial to evaluate

Read the full 112 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE